سعر ايفيميند 150 مجم محلول 2022

Fosaprepitant 150 mg powder for solution for intravenous infusion (vial), an NK1 receptor antagonist prodrug of aprepitant used with a 5-HT3 antagonist and a corticosteroid to prevent chemotherapy-induced nausea and vomiting.

• Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, as part of combination therapy.Population: Adults and paediatric patients aged 6 months and olderEuropean Medicines Agency (EPAR product information)
• In combination with other antiemetics, prevention of acute and delayed nausea and vomiting with initial and repeat courses of highly emetogenic chemotherapy (including high-dose cisplatin), and of delayed nausea and vomiting with moderately emetogenic chemotherapy; not studied for established nausea and vomiting.Population: Adults and pediatric patients 6 months of age and olderDailyMed (U.S. National Library of Medicine)

• Most common with the aprepitant regimen in adults on HEC: hiccups, increased ALT, dyspepsia, constipation, headache and decreased appetite; fatigue with MEC; in children hiccups and flushing. Dizziness and fatigue may affect driving.International label, same product · European Medicines Agency (EPAR product information)
• Most common in adults on MEC with the EMEND regimen (vs standard therapy): fatigue 15%, diarrhoea 13%, neutropenia 8%, asthenia 4%, anaemia 3%, peripheral neuropathy 3%; infusion-site reactions occurred in 3.0% of HEC patients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to fosaprepitant, polysorbate 80 or any excipient; co-administration with pimozide, terfenadine, astemizole or cisapride.International label, same product · European Medicines Agency (EPAR product information)
• Hypersensitivity to any component (anaphylaxis, flushing, erythema, dyspnoea reported); patients taking pimozide (CYP3A4 inhibition may raise pimozide levels and cause QT prolongation).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Use with caution with CYP3A4 substrates of narrow therapeutic range (e.g. ciclosporin, tacrolimus, sirolimus, everolimus, alfentanil, ergot derivatives, fentanyl, quinidine); particular caution with irinotecan.International label, same product · European Medicines Agency (EPAR product information)
• Immediate hypersensitivity reactions (flushing, erythema, dyspnoea, anaphylaxis/anaphylactic shock) may occur during or soon after infusion; do not re-start the infusion in patients who react.International label, same product · European Medicines Agency (EPAR product information)
• Infusion site reactions, including severe thrombophlebitis, vasculitis and necrosis, mostly with concomitant vesicant (e.g. anthracycline) chemotherapy and extravasation; stop and restart in another vein if local irritation occurs.International label, same product · European Medicines Agency (EPAR product information)

• PimozideContraindicated: CYP3A4 inhibition by aprepitant may markedly raise pimozide levels (QT prolongation).DailyMed (U.S. National Library of Medicine)
• DexamethasoneReduce the dexamethasone dose by 50% on Days 1-2 (US label); the EU dexamethasone regimen already accounts for the interaction.DailyMed (U.S. National Library of Medicine)
• WarfarinClinically significant INR decrease; monitor INR closely (EU: for 14 days after fosaprepitant).European Medicines Agency (EPAR product information)

• No clinical data on exposed pregnancies; animal studies did not show harmful effects but could not reach exposures above human levels; IVEMEND should not be used during pregnancy unless clearly necessary.International label, same product · European Medicines Agency (EPAR product information)
• Insufficient data in pregnant women to inform a drug-associated risk; no adverse developmental effects in rats or rabbits at exposures about equal to the 150 mg human dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Aprepitant is excreted in rat milk; human data unknown; breast-feeding is not recommended during treatment.International label, same product · European Medicines Agency (EPAR product information)

• Fosaprepitant: Prodrug rapidly converted to aprepitant, a selective high-affinity antagonist of human substance P/NK1 receptors; little or no affinity for 5-HT3, dopamine or corticosteroid receptors; augments the antiemetic effect of 5-HT3 antagonists and dexamethasone against acute and delayed chemotherapy-induced emesis.